Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
PSDV's Cash to Debt is ranked higher than
98% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. PSDV: No Debt )
PSDV' s 10-Year Cash to Debt Range
Min: 0.47   Max: No Debt
Current: No Debt

Equity to Asset 0.80
PSDV's Equity to Asset is ranked higher than
86% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. PSDV: 0.80 )
PSDV' s 10-Year Equity to Asset Range
Min: 0.47   Max: 0.91
Current: 0.8

0.47
0.91
Interest Coverage No Debt
PSDV's Interest Coverage is ranked higher than
94% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 176.76 vs. PSDV: No Debt )
PSDV' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 7
Z-Score: 2.52
M-Score: 7.03
WACC vs ROIC
5.76%
594.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 37.14
PSDV's Operating margin (%) is ranked higher than
97% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.26 vs. PSDV: 37.14 )
PSDV' s 10-Year Operating margin (%) Range
Min: -4862.16   Max: 39.44
Current: 37.14

-4862.16
39.44
Net-margin (%) 36.77
PSDV's Net-margin (%) is ranked higher than
98% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.01 vs. PSDV: 36.77 )
PSDV' s 10-Year Net-margin (%) Range
Min: -4638.7   Max: 37.97
Current: 36.77

-4638.7
37.97
ROE (%) 45.36
PSDV's ROE (%) is ranked higher than
99% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. PSDV: 45.36 )
PSDV' s 10-Year ROE (%) Range
Min: -133.19   Max: 30.94
Current: 45.36

-133.19
30.94
ROA (%) 33.69
PSDV's ROA (%) is ranked higher than
99% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. PSDV: 33.69 )
PSDV' s 10-Year ROA (%) Range
Min: -95.61   Max: 21.85
Current: 33.69

-95.61
21.85
ROC (Joel Greenblatt) (%) 206.26
PSDV's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.87 vs. PSDV: 206.26 )
PSDV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -17260.3   Max: 16680.73
Current: 206.26

-17260.3
16680.73
Revenue Growth (3Y)(%) -19.60
PSDV's Revenue Growth (3Y)(%) is ranked higher than
52% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. PSDV: -19.60 )
PSDV' s 10-Year Revenue Growth (3Y)(%) Range
Min: -58.1   Max: 85
Current: -19.6

-58.1
85
EBITDA Growth (3Y)(%) 10.60
PSDV's EBITDA Growth (3Y)(%) is ranked higher than
80% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. PSDV: 10.60 )
PSDV' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 86.4
Current: 10.6

0
86.4
EPS Growth (3Y)(%) 3.70
PSDV's EPS Growth (3Y)(%) is ranked higher than
75% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.30 vs. PSDV: 3.70 )
PSDV' s 10-Year EPS Growth (3Y)(%) Range
Min: -71.5   Max: 108.1
Current: 3.7

-71.5
108.1
» PSDV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

PSDV Guru Trades in Q4 2013

Jim Simons 57,000 sh (-76.43%)
» More
Q1 2014

PSDV Guru Trades in Q1 2014

Jim Simons Sold Out
» More
Q3 2014

PSDV Guru Trades in Q3 2014

Jim Simons 125,100 sh (New)
» More
Q4 2014

PSDV Guru Trades in Q4 2014

Jim Simons 68,400 sh (-45.32%)
» More
» Details

Insider Trades

Latest Guru Trades with PSDV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 12.80
PSDV's P/E(ttm) is ranked higher than
96% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 52.50 vs. PSDV: 12.80 )
PSDV' s 10-Year P/E(ttm) Range
Min: 8.22   Max: 37.86
Current: 12.8

8.22
37.86
PE(NRI) 13.00
PSDV's PE(NRI) is ranked higher than
96% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 51.50 vs. PSDV: 13.00 )
PSDV' s 10-Year PE(NRI) Range
Min: 8.18   Max: 37.41
Current: 13

8.18
37.41
P/B 3.66
PSDV's P/B is ranked higher than
69% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. PSDV: 3.66 )
PSDV' s 10-Year P/B Range
Min: 0.43   Max: 11.73
Current: 3.66

0.43
11.73
P/S 4.38
PSDV's P/S is ranked higher than
65% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.38 vs. PSDV: 4.38 )
PSDV' s 10-Year P/S Range
Min: 1.02   Max: 1600
Current: 4.38

1.02
1600
PFCF 9.60
PSDV's PFCF is ranked higher than
98% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1165.60 vs. PSDV: 9.60 )
PSDV' s 10-Year PFCF Range
Min: 4.95   Max: 105
Current: 9.6

4.95
105
POCF 9.60
PSDV's POCF is ranked higher than
95% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.96 vs. PSDV: 9.60 )
PSDV' s 10-Year POCF Range
Min: 7.11   Max: 35
Current: 9.6

7.11
35
EV-to-EBIT 7.92
PSDV's EV-to-EBIT is ranked higher than
97% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.80 vs. PSDV: 7.92 )
PSDV' s 10-Year EV-to-EBIT Range
Min: -430.1   Max: 37.5
Current: 7.92

-430.1
37.5
Current Ratio 16.43
PSDV's Current Ratio is ranked higher than
98% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. PSDV: 16.43 )
PSDV' s 10-Year Current Ratio Range
Min: 0.26   Max: 17.6
Current: 16.43

0.26
17.6
Quick Ratio 16.43
PSDV's Quick Ratio is ranked higher than
98% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. PSDV: 16.43 )
PSDV' s 10-Year Quick Ratio Range
Min: 0.26   Max: 17.6
Current: 16.43

0.26
17.6
Days Sales Outstanding 9.44
PSDV's Days Sales Outstanding is ranked higher than
97% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. PSDV: 9.44 )
PSDV' s 10-Year Days Sales Outstanding Range
Min: 17.59   Max: 493.85
Current: 9.44

17.59
493.85

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.25
PSDV's Price/Net Cash is ranked higher than
96% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. PSDV: 4.25 )
PSDV' s 10-Year Price/Net Cash Range
Min: 2.02   Max: 246
Current: 4.25

2.02
246
Price/Net Current Asset Value 4.03
PSDV's Price/Net Current Asset Value is ranked higher than
94% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. PSDV: 4.03 )
PSDV' s 10-Year Price/Net Current Asset Value Range
Min: 1.82   Max: 316
Current: 4.03

1.82
316
Price/Tangible Book 3.95
PSDV's Price/Tangible Book is ranked higher than
74% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. PSDV: 3.95 )
PSDV' s 10-Year Price/Tangible Book Range
Min: 1.76   Max: 105.33
Current: 3.95

1.76
105.33
Price/DCF (Projected) 6.39
PSDV's Price/DCF (Projected) is ranked higher than
76% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.70 vs. PSDV: 6.39 )
PSDV' s 10-Year Price/DCF (Projected) Range
Min: 6.52   Max: 6.52
Current: 6.39

Price/Median PS Value 0.26
PSDV's Price/Median PS Value is ranked higher than
98% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. PSDV: 0.26 )
PSDV' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 80
Current: 0.26

0.1
80
Price/Graham Number 1.42
PSDV's Price/Graham Number is ranked higher than
90% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.78 vs. PSDV: 1.42 )
PSDV' s 10-Year Price/Graham Number Range
Min: 1.44   Max: 3.87
Current: 1.42

1.44
3.87
Earnings Yield (Greenblatt) 12.60
PSDV's Earnings Yield (Greenblatt) is ranked higher than
97% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. PSDV: 12.60 )
PSDV' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.7   Max: 18.4
Current: 12.6

2.7
18.4

Analyst Estimate

Jun15
EPS($) -0.29
EPS without NRI($) -0.29

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:PVA.Australia, PV3.Germany, PV3A.Germany, PSIZF.USA,
pSivida Ltd was organized as a Delaware Corporation in March 2008. On June 19, 2008, it reincorporated from Western Australia to the United States. The Company develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. It is focused on treatment of chronic diseases of the back of the eye utilizing its core technology platforms, Durasert and BioSilicon. It currently has three approved products, as well as two current product candidates in clinical trials, use different generations of this technology system. It has developed three of the four sustained release devices for treatment of retinal diseases currently approved in the U.S. or the European Union (EU). ILUVIEN, its recently approved product, is an injectable, sustained-release micro-insert that provides treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies over a period of up to three years. ILUVIEN is being developed by its licensee Alimera Sciences, Inc. (Alimera). ILUVIEN has received marketing authorization in the United Kingdom, Austria, France, Germany and Portugal, and marketing authorization is pending in Italy and Spain. The International Diabetes Federation has estimated that approximately 19.0 million people have diabetes in the seven EU countries where ILUVIEN has received or been recommended for marketing authorization, of which Alimera has estimated that approximately 1.1 million people suffer from vision loss associated with DME. Alimera is also seeking marketing approval for ILUVIEN for DME in the U.S. Alimera has announced its intention to launch in France in the first quarter of 2014. It faces substantial competition for its products and product candidates. Its competitors and potential competitors are larger, better established and more experienced and have substantially more resources than the Company or its partners. Durasert, Medidur, Tethadur and BioSilicon are its trademarks.
» More Articles for PSDV

Headlines

Articles On GuruFocus.com
pSivida Ltd. Reports Operating Results (10-Q) Feb 10 2011 
pSivida Ltd. Reports Operating Results (10-Q) Nov 09 2010 
pSivida Ltd. Reports Operating Results (10-K) Sep 27 2010 
pSivida Ltd. Reports Operating Results (10-Q) May 13 2010 
pSivida Ltd. Reports Operating Results (10-Q) Feb 12 2010 
pSivida Ltd. Reports Operating Results (10-Q) Nov 13 2009 
pSivida Ltd. Reports Operating Results (10-K) Sep 25 2009 
pSivida Ltd. Reports Operating Results (10-Q) May 13 2009 
pSivida Ltd. Reports Operating Results (10-Q) Feb 12 2009 
pSivida Corp. Reports Results for the Second Quarter Ended December 31, 2008; Iluvien™ NDA filing Feb 11 2009 

More From Other Websites
pSivida Corp. Completes Targeted Enrollment of Phase III Trial of Medidur™ for Posterior Uveitis Mar 26 2015
pSivida Corp. Completes Targeted Enrollment of Phase III Trial of Medidur™ for Posterior Uveitis Mar 26 2015
pSivida Announces U.S. Shipments of ILUVIEN® for DME to Start February 23 Feb 17 2015
pSivida Announces U.S. Shipments of ILUVIEN® for DME to Start February 23 Feb 17 2015
pSivida Announces U.S. Shipments of ILUVIEN® for DME to Start February 23 Feb 17 2015
PSIVIDA CORP. Financials Feb 13 2015
10-Q for pSivida Corp. Feb 08 2015
PSIVIDA CORP. Files SEC form 10-Q, Quarterly Report Feb 06 2015
PSivida reports 2Q loss Feb 05 2015
PSivida reports 2Q loss Feb 05 2015
PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 05 2015
pSivida Corp. Reports Second Quarter FY 2015 Results Feb 05 2015
pSivida CEO to Present at 17Th Annual BioCEO & Investor Conference February 9 Feb 03 2015
pSivida Corp. Announces Second Quarter Fiscal Year 2015 Financial Results Release Date and... Jan 30 2015
pSivida Corp. Announces Second Quarter Fiscal Year 2015 Financial Results Release Date and... Jan 30 2015
pSivida Reports ILUVIEN® Receives Marketing Authorization in Two More EU Countries Jan 26 2015
pSivida Reports ILUVIEN® Receives Marketing Authorization in Two More EU Countries Jan 26 2015
pSivida Reports Commencement of ILUVIEN® Sales in Portugal Jan 14 2015
PSIVIDA CORP. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Dec 15 2014
pSivida Reports ILUVIEN® Granted Marketing Authorization in the Netherlands Dec 01 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK